US20030113316A1 - Stable lyophilized pharmaceutical formulation of IgG antibodies - Google Patents

Stable lyophilized pharmaceutical formulation of IgG antibodies Download PDF

Info

Publication number
US20030113316A1
US20030113316A1 US10/206,469 US20646902A US2003113316A1 US 20030113316 A1 US20030113316 A1 US 20030113316A1 US 20646902 A US20646902 A US 20646902A US 2003113316 A1 US2003113316 A1 US 2003113316A1
Authority
US
United States
Prior art keywords
formulation
antibody
lyophilized
sucrose
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/206,469
Other languages
English (en)
Inventor
Elizabet Kaisheva
Aleni Flores-Nate
Supriya Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to US10/206,469 priority Critical patent/US20030113316A1/en
Assigned to PROTEIN DESIGN LABS, INC. reassignment PROTEIN DESIGN LABS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FLORES-NATE, ALENI, GUPTA, SUPRIYA, KAISHEVA, ELIZABET A.
Publication of US20030113316A1 publication Critical patent/US20030113316A1/en
Priority to US11/250,835 priority patent/US7592004B2/en
Priority to US12/540,320 priority patent/US8298530B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • the present invention relates generally to the field of pharmaceutical formulation of antibodies. Specifically, the present invention relates to a stable, lyophilized, high concentration antibody formulation. This invention is exemplified by a stabilized lyophilized formulation of anti-IL 2 receptor antibody.
  • Immunoglobulins are recognized as possessing characteristics that tend to form aggregates and particulates in solution; thus requiring filtration of these formulations prior to using them for intravenous injection.
  • the formation of protein aggregates and particulates has long been a problem in the development of parenteral immunoglobulin products.
  • a stable pharmaceutical formulation comprising an antibody.
  • WO 89/11297 discloses a lyophilized composition
  • SynagisTM (MedImmune) is a humanized monoclonal IgG1 antibody produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the T protein of respiratory syncytial virus (RSV).
  • SynagisTM is a composite of human (95%) and murine (5%) antibody sequences.
  • SynagisTM is supplied as a sterile lyophilized product for reconstruction with sterile water for injection. Reconstituted SynagisTM is required to stand at room temperature for a minimum of 20 minutes until the solution clarifies. Reconstituted SynagisTM is to be administered by intramuscular injection only.
  • SynagisTM contains the following excipients: 47 mM histidine, 3.0 mM glycine and 5.6% mannitol and the active ingredient, IgG1 antibody, at a concentration of 100 milligrams per vial. (See Physicians' Desk Reference®, Medical Economic Company, Inc., Montvale, N.J.)
  • U.S. Patent Application Publication No. U.S. 2001/0014326A1 discloses a prelyophilized antibody formulation containing 25 mg/ml anti-IgE antibody, 5 mM histidine, pH 6.0, 85 mM sucrose, and 0.01% polysorbate 20.
  • U.S. Pat. No. 6,171,586 discloses a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, and acetate buffer from about pH 4.8 to about 5.5, a surfactant, and a polyol, wherein the formulation lacks a tonicifying amount of sodium chloride.
  • WO 97/45140 discloses a monoclonal antibody preparation of a humanized antibody against the CDw52 antigen, having a concentration of 100 mg/ml or greater, wherein the preparation is substantially free from aggregates.
  • Cleland, et al. J. Pharm. Sci., 90:310-321 (2001) disclose that a 360:1 molar ratio of lyoprotectant to protein is required for storage stability of a lyophilized monoclonal antibody.
  • This invention is directed to a stable lyophilized pharmaceutical formulation prepared from an aqueous formulation comprising a high concentration, e.g., greater than 50 mg/ml of an IgG antibody in about 5-25 mM histidine buffer (pH from about 5.5 to about 6.5), about 0.005%-0.03% polysorbate, and sucrose, optionally in combination with serine, and/or mannitol.
  • This formulation retains the stability of the IgG antibody, and prevents the immunoglobulins intended for administration to human subjects from forming aggregates/particulates in the final product.
  • the lyophilized formulation is reconstituted with a liquid to a clarified solution containing greater than 50 mg/ml IgG antibody concentration within about 2 minutes or less.
  • This lyophilized formulation is stable at room temperature for at least 3 months, preferably 6 months, and more preferably 1 year.
  • the lyophilized formulation is also stable at 2-8° C. for 1 year, preferably 2 years.
  • This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection.
  • FIG. 1 shows the effect of excipients on antibody stability by testing (A) the liquid after storage at 55° C. for 10 days and (B) the lyophile at 40° C. for 12 days.
  • FIGS. 2A and 2B show the comparison of model predictions and experimental observation for the test samples 1 - 15 .
  • FIG. 2A shows the % drop in monomer.
  • FIG. 2B shows the reconstruction time.
  • FIGS. 3A and 3B show the comparison of model predictions and experimental observation for the control samples 16 - 20 .
  • FIG. 3A shows the % drop in monomer.
  • FIG. 3B shows the reconstitution time.
  • FIG. 4 shows the model coefficients of (A) main effect, and (B) interaction effect.
  • FIG. 5A shows the % monomer drop.
  • FIG. 5B shows the reconstitution time.
  • FIG. 6A shows the % monomer drop.
  • FIG. 6B shows the reconstitution time.
  • FIG. 7A shows the % monomer drop.
  • FIG. 7B shows the reconstitution time.
  • FIG. 8A shows the % monomer drop.
  • FIG. 8B shows the reconstitution time.
  • FIGS. 9 A- 9 C show percent monomer in Formulations I, II and II as a function of time at (A) 5° C., (B) 25° C., and (C) 40° C.
  • FIGS. 10 A-C show percent aggregates in Formulations I, II and III as a function of time at (A) 5° C., (B) 25° C., and (C) 40° C.
  • FIGS. 11 A-C shows percent clips in Formulations I, II and III as a function of time at (A) 5° C., (B) 25° C., and (C) 40° C.
  • bulking agents comprise agents that provide the structure of the freeze-dried product.
  • Common examples used for bulking agents include mannitol, glycine, lactose and sucrose.
  • bulking agents may also impart useful qualities in regard to modifying the collapse temperature, providing freeze-thaw protection, and enhancing the protein stability over long-term storage. These agents can also serve as tonicity modifiers.
  • buffer encompasses those agents which maintain the solution pH in an acceptable range prior to lyophilization and may include succinate (sodium or potassium), histidine, phosphate (sodium or potassium), Tris(tris(hydroxymethyl)aminomethane), diethanolamine, citrate (sodium) and the like.
  • the buffer of this invention has a pH in the range from about 5.5 to about 6.5; and preferably has a pH of about 6.0. Examples of buffers that will control the pH in this range include succinate (such as sodium succinate), gluconate, histidine, citrate and other organic acid buffers.
  • cryoprotectants generally includes agents which provide stability to the protein against freezing-induced stresses, presumably by being preferentially excluded from the protein surface. They may also offer protection during primary and secondary drying, and long-term product storage. Examples are polymers such as dextran and polyethylene glycol; sugars such as sucrose, glucose, trehalose, and lactose; surfactants such as polysorbates; and amino acids such as glycine, arginine, and serine.
  • lyophilization refers to a process by which the material to be dried is first frozen and then the ice or frozen solvent is removed by sublimation in a vacuum environment.
  • An excipient may be included in pre-lyophilized formulations to enhance stability of the lyophilized product upon storage.
  • lyoprotectant includes agents that provide stability to the protein during the drying or ‘dehydration’ process (primary and secondary drying cycles), presumably by providing an amorphous glassy matrix and by binding with the protein through hydrogen bonding, replacing the water molecules that are removed during the drying process. This helps to maintain the protein conformation, minimize protein degradation during the lyophilization cycle and improve the long-term product stability.
  • examples include polyols or sugars such as sucrose and trehalose.
  • pharmaceutical formulation refers to preparations which are in such form as to permit the active ingredients to be effective, and which contains no additional components which are toxic to the subjects to which the formulation would be administered.
  • “Pharmaceutically acceptable” excipients are those which can reasonably be administered to a subject mammal to provide an effective dose of the active ingredient employed.
  • Reconstitution time is the time that is required to rehydrate a lyophilized formulation with a solution to a particle-free clarified solution.
  • a “stable” formulation is one in which the protein therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage.
  • Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993). Stability can be measured at a selected temperature for a selected time period.
  • a “stable” lyophilized antibody formulation is a lyophilized antibody formulation with no significant changes observed at a refrigerated temperature (2-8° C.) for at least 12 months, preferably 2 years, and more preferably 3 years; or at room temperature (23-27° C.) for at least 3 months, preferably 6 months, and more preferably 1 year.
  • the criteria for stability are as follows. No more than 10%, preferably 5%, of antibody monomer is degraded as measured by SEC-HPLC. The rehydrated solution is colorless, or clear to slightly opalescent by visual analysis. The concentration, pH and osmolality of the formulation have no more than +/ ⁇ 10% change. Potency is within 70-130, preferably 80-120% of the control. No more than 10%, preferably 5% of clipping is observed. No more than 10%, preferably 5% of aggregation is formed.
  • An antibody “retains its physical stability” in a pharmaceutical formulation if it shows no significant increase of aggregation, precipitation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering, size exclusion chromatography (SEC) and dynamic light scattering.
  • SEC size exclusion chromatography
  • the changes of protein conformation can be evaluated by fluorescence spectroscopy, which determines the protein tertiary structure, and by FTIR spectroscopy, which determines the protein secondary structure.
  • An antibody “retains its biological activity” in a pharmaceutical formulation, if the biological activity of the antibody at a given time is within a predetermined range of the biological activity exhibited at the time the pharmaceutical formulation was prepared.
  • the biological activity of an antibody can be determined, for example, by an antigen binding assay.
  • isotonic means that the formulation of interest has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure from about 270-328 mOsm. Slightly hypotonic pressure is 250-269 and slightly hypertonic pressure is 328-350 mOsm. Osmotic pressure can be measured, for example, using a vapor pressure or ice-freezing type osmometer.
  • Tonicity Modifiers Salts (NaCl, KCl, MgCl 2 , CaCl 2 , etc) are used as tonicity modifiers to control osmotic pressure.
  • cryprotecants/lyoprotectants and/or bulking agents such as sucrose, mannitol, glycine etc. can serve as tonicity modifiers.
  • the analytical methods for evaluating the product stability include size exclusion chromatography (SEC), dynamic light scattering test (DLS), differential scanning calorimetery (DSC), iso-asp quantification, potency, UV at 340 nm, UV spectroscopy, and FTIR.
  • SEC size exclusion chromatography
  • DSC differential scanning calorimetery
  • iso-asp quantification potency, UV at 340 nm, UV spectroscopy, and FTIR.
  • SEC J. Pharm. Scien., 83:1645-1650, (1994); Pharm. Res., 11:485 (1994); J. Pharm. Bio. Anal., 15:1928 (1997); J. Pharm. Bio. Anal., 14:1133-1140 (1986)
  • DSC Pharm. Res., 15:200 (1998); Pharm.
  • the iso-asp content in the samples is measured using the Isoquant Isoaspartate Detection System (Promega).
  • the kit uses the enzyme Protein Isoaspartyl Methyltransferase (PIMT) to specifically detect the presence of isoaspartic acid residues in a target protein.
  • PIMT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to isoaspartic acid at the ⁇ -carboxyl position, generating S-adenosyl-L-homocysteine (SAH) in the process.
  • SAH S-adenosyl-L-homocysteine
  • the potency or bioidentity of an antibody can be measured by its ability to bind to its antigen.
  • the specific binding of an antibody to its antigen can be quantitated by any method known to those skilled in the art, for example, an immunoassay, such as ELISA (enzyme-linked immunosorbant assay).
  • the invention herein relates to a stable formulation comprising an antibody.
  • the antibody is prepared using techniques available in the art for generating antibodies, exemplary methods of which are described in more detail in the following sections.
  • the antibody is directed against an antigen of interest.
  • the antigen is a biologically important polypeptide and administration of the antibody to a mammal may prevent or treat a disorder.
  • antibodies directed against nonpolypeptide antigens are also contemplated.
  • the antigen is a polypeptide, it may be a transmembrane molecule (e.g. receptor) or ligand such as a growth factor.
  • exemplary antigens include molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and
  • the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed cells, is removed, for example, by centrifugation or ultrafiltration. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • the antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique.
  • affinity chromatography is the preferred purification technique.
  • the suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
  • Protein A can be used to purify antibodies that are based on human ⁇ 1 , ⁇ 2 , or ⁇ 4 heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human ⁇ 3 (Guss et al., EMBO J.
  • the matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose.
  • the antibody comprises a C H3 domain
  • the Bakerbond ABXTM resin J. T. Baker, Phillipsburg, N.J. is useful for purification.
  • a preferred antibody encompassed by the present invention is an IgG antibody.
  • This invention is exemplified by an anti-IL-2 receptor antibody such as Daclizumab.
  • Daclizumab is a recombinant humanized monoclonal antibody, subclass IgG1. The molecule is composed of two identical heavy chain and two identical light chain subunits. Disulfide bridges link the four chains. Daclizumab monomer is approximately 150,000 daltons in molecular weight. Daclizumab binds to the p55 subunit of the IL-2 receptor expressed on activated T cells. The antigen target is designated CD25. Daclizumab is produced from a GS-NS0 cell line containing the heavy and light chain genes by fed- batch fermentation culture. Bioreactor harvests are processed to remove cells and debris and purified using a combination of ion-exchange and gel filtration chromatography and a series of ultrafiltration and filtration techniques to produce drug substance containing greater than 95% monomeric species.
  • the pharmaceutical formulation comprising the antibody is prepared.
  • the formulation development approach is as follows: selecting the optimum solution pH, selecting buffer type and concentration, evaluating the effect of various excipients of the liquid and lyophilized stability, and optimizing the concentration of the screened excipients using an I-optimal experimental design (Statistics for Experimental, Box, George E. P. John Wiley and Sons, Inc., 1978).
  • the following criteria are important in developing stable lyophilized protein products. Protein unfolding during lyophilization should be minimized. Various degradation pathways should be minimized. Glass transition temperature (Tg) should be greater than the product storage temperature. Residual moisture should be low ( ⁇ 1% by mass). A strong and elegant cake structure should be obtained. A preferred shelf life should be at least 3 months, preferably 6 months, more preferably 1 year at room temperature (22 to 28° C.). A reconstitution time should be short, for example, less than 5 minutes, preferably less than 2 minutes, and more preferably less than 1 minute. When the lyophilized product is reconstituted, the reconstituted sample should be stable for at least 48 hours at 2-8° C.
  • compositions of this invention minimize the formation of protein aggregates and particulates in reagents containing immunoglobulin antibodies and insure that the antibody in solution maintains its immunoreactivity over time.
  • the composition comprises a sterile, pharmaceutically acceptable lyophilized formulation prepared from an aqueous pre-lyophilized formulation comprising an antibody in a buffer having a neutral or acidic pH (pH 5.5-6.5), a surfactant, and a polyol.
  • the preferred composition additionally contains a bulking agent, and/or a tonicity modifier.
  • the antibody in the pre-lyophilized formulation has a high concentration of 50 mg/ml or greater.
  • a preferred antibody is an IgG antibody, preferably a monoclonal IgG antibody.
  • a buffer of pH 5.5-6.5 is used in the composition.
  • buffers that control the pH in this range include succinate (such as sodium succinate), gluconate, histidine, citrate and other organic acid buffers. Histidine is a preferred buffer for subcutaneous, intramuscular and peritoneal injection.
  • Sodium succinate buffer is less preferred because it does not have a good buffer capacity at low strength.
  • the amount of the excipients will have to be decreased in order to maintain the osmolarity in a desired range. If the lyophile is to be reconstituted with half of the fill volume, then the desired osmolarity of the pre-lyophilized (fill) liquid is about 140-160 mOsm.
  • histidine buffer is that 1 mmole of the histidine buffer only contributes 1 mOsm, whereas 1 mmole of the sodium succinate buffer contributes 3 mOsm. Because histidine buffer contributes less to the osmolarity, it allows more stabilizing excipients to be added to the formulation. Citrate buffer is also less preferred because it causes a painful reaction when injected subcutaneously. A preferred buffer contains about 5-25 mM histidine. A more preferred buffer contains about 10-20 mM histidine.
  • a surfactant is added to the antibody formulation.
  • exemplary surfactants include nonionic surfactants such as polysorbates (e.g. polysorbates 20, 80, such as Tween®20, Tween®80) or poloxamers (e.g. poloxamer 188).
  • the amount of surfactant added is such that it reduces aggregation of the formulated antibody and/or minimizes the formation of particulates in the formulation and/or reduces protein adsorption onto the container.
  • the surfactant also reduces the reconstitution time of the lyophilized formulation.
  • the surfactant is present in the formulation in an amount from about 0.001% to about 0.5%, preferably from about 0.005% to about 0.1% and most preferably from about 0.01% to about 0.05%.
  • a polyol which acts as a tonicifying agent and a cryoprotector/lyoprotector, is included in the formulation.
  • the polyol is a nonreducing sugar, such as sucrose or trehalose.
  • the polyol such as sucrose is the primary stabilizer against antibody aggregation, and it also plays an important role in reducing the reconstitution time of the lyophilized formulation to a particle-free solution.
  • the polyol is added to the formulation in an amount that may vary with respect to the desired tonicity of the formulation.
  • the lyophilized formulation after reconstitution is isotonic; however, hypertonic or hypotonic formulations may also be suitable.
  • Suitable concentrations of the polyol such as sucrose in the pre-lyophilized formulation are in the range from about 100-300 mM, preferably in the range from about 100-200 mM.
  • a bulking agent that provides good lyophilized cake properties such as serine, glycine, mannitol, can be optionally added to the present composition. These agents also contribute to the tonicity of the formulations and may provide protection to the freeze-thaw process and improve long-term stability.
  • a preferred bulking agent is serine at a concentration about 15-55 mM, and preferably about 20-30 mM.
  • Another preferred bulking agent is mannitol, at a concentration about 10-55 mM, and preferably about 20-45 mM.
  • the addition of serine or mannitol to the pre-lyophilized formulation reduces the concentration of polyol required for stabilizing the antibody, for example, to 30-180 mM and preferably 80-130 mM.
  • Tonicity modifiers such as salts (e.g., NaCl, KCl, MgCl 2 , CaCl 2 ) can be added to the formulation to control osmotic pressure.
  • salts e.g., NaCl, KCl, MgCl 2 , CaCl 2
  • Exemplary pre-lyophilized compositions are formulations comprising an IgG antibody at about 50 mg/ml or greater, about 10-20 mM histidine (pH 5.5-6.5), about 0.005-0.03 % polysorbate 20 or 80, and one of the following combinations of excipients: (a) 100-200 mM sucrose, (b) 110-130 mM sucrose and 20-45 mM mannitol, (c) 100-130 mM sucrose and 15-55 mM serine, and (d) 7-55 mM serine, 80-130 mM sucrose, and 10-55 mM mannitol.
  • the above pre-lyophilized formulation is lyophilized to form a dry, stable powder, which can be easily reconstituted to a particle-free solution suitable for administering to humans.
  • Lyophilization is a freeze drying process that is often used in the preparation of pharmaceutical products to preserve their biological activity.
  • the liquid composition is prepared, then lyophilized to form a dry cake-like product.
  • the process generally involves drying a previously frozen sample in a vacuum to remove the ice, leaving the non-water components intact, in the form of a powdery or cake-like substance.
  • the lyophilized product can be stored for prolonged periods of time, and at elevated temperatures, without loss of biological activity, and can be readily reconstituted into a particle-free solution by the addition of an appropriate diluent.
  • An appropriate diluent can be any liquid which is biologically acceptable and in which the lyophilized powder is completely soluble.
  • Water particularly sterile, pyrogen-free water, is a preferred diluent, since it does not include salts or other compounds which may affect the stability of the antibody.
  • the advantage of lyophilization is that the water content is reduced to a level that greatly reduce the various molecular events which lead to instability of the product upon long-term storage.
  • the lyophilized product is also more readily able to withstand the physical stresses of shipping.
  • the reconstituted product is particle free, thus it can be administered without prior filtration.
  • the liquid formulation can be lyophilized using appropriate drying parameters.
  • drying parameters are preferred: a primary drying phase temperature of about ⁇ 20° C. to ⁇ 50° C. and pressure between about 80 mTorr to about 120 mTorr; and a secondary drying phase at ambient temperature, and pressure between about 80 mTorr to 120 mTorr.
  • This lyophilized product retains the stability of immunological activity of the monoclonal antibody, and prevents the immunoglobulins intended for administration to human subjects from physical and chemical degradation in the final product.
  • the lyophilized product is rehydrated at the time of use in a diluent (e.g., sterile water or saline) to yield a particle-free solution.
  • a diluent e.g., sterile water or saline
  • the reconstituted antibody solution is particle-free even after prolonged storage of the lyophilized cake at ambient temperature.
  • the reconstituted solution is administered parenterally, preferably intravenously or subcutaneously, to the subject.
  • An important characteristic of the lyophilized product is the reconstitution time or the time taken to rehydrate the product. To enable very fast and complete rehydration, it is important to have a cake with a highly porous structure.
  • the cake structure is a function of a number of parameters including the protein concentration, excipient type and concentration, and the process parameters of the lyophilization cycle.
  • the reconstitution time increases as the protein concentration increases, and thus, a short reconstitution time is an important goal in the development of high concentration lyophilized antibody formulations.
  • a long reconstitution time can deteriorate the product quality due to the longer exposure of the protein to a more concentrated solution.
  • the product cannot be administered until the product is completely rehydrated. This is to ensure that the product is particulate-free, the correct dosage is administered, and its sterility is unaffected.
  • quick rehydration offers more convenience to the patients and the physicians.
  • the desired dosage can be obtained by lyophilizing the formulation at the target protein concentration and reconstituting the product with the same volume as that of the starting fill volume.
  • the desired dosage can also be obtained by lyophilizing a larger volume of a diluted formulation, and reconstituting it with a less volume.
  • a desired product dosage is 100 mg of protein in 1 mL of the formulation
  • the formulations can be lyophilized with the following liquid configurations: 1 mL of 100 mg/mL, 2 mL of 50 mg/ml, or 4 mL of 25 mg/mL protein formulation.
  • the final product can be reconstituted with 1 mL diluent to obtain the target protein concentration of 100 mg/mL.
  • the fill volume increases proportionately. This correspondingly increases the length of the lyophilization cycle (especially the primary drying time), and thus significantly adds to the cost of the product. For example, if 1 mL fill volume (1 mm height in vial) of frozen material takes approximately 1 hour to sublimate its free water, then 10 mL fill volume (10 mm height) of frozen product will take approximately 10 hours of primary drying time. Therefore, it is advantageous to have a concentrated pre-lyophilized formulation (with antibody greater than 50 mg/mL) such that the lyophilization process will be more efficient.
  • the present invention provides a highly concentrated pre-lyophilized antibody formulation (greater than 50 mg/mL), which is lyophilized efficiently and effectively to a dry formulation that retains the biological, physical and chemical stability of the antibody.
  • the dry formulation is stable for storage at least for 3 months, preferably 6 months, at room temperature.
  • the dry formulation can be reconstituted within a short time of less than 2 minutes to a particle-free solution containing greater than 50 mg/mL antibody.
  • Such highly concentrated antibody solution is ready for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection.
  • Rate 2° C./min
  • Rate 1° C./min
  • Rate 1° C./min
  • the formulation matrix contains 10 mg/ml anti-IL2 receptor antibody, 10 mM histidine, pH 6.0, and 0.015% Tween®80.
  • the excipients screened includes (a) cryoprotectors/lyoprotectors such as sucrose, trehalose, polyethylene glycol (PEG), and polyvinylpyrrolidone (PVP); (b) bulking agents and tonicity modifiers such as mannitol, glycine, and serine; and (c) Tg enhancers such as dextran.
  • sucrose, mannitol and serine were investigated using an I-Optimal (Hardin-Sloane) experimental design approach.
  • the formulation matrix contains 50 mg/ml anti-IL2 receptor antibody, 10 mM histidine, pH 6.0, and 0.015% Tween®80.
  • the excipients screened include serine (0-100 mM), sucrose (0-120 mM) and mannitol (0-170 mM).
  • the I-Optimal Design is shown as Table 1. Samples 1-15 are test formulations, and samples 16-20 are control formulations.
  • the lyophile product stability test was performed at 37° C. for 4 weeks. The formulations were distinguishable. The analytic methods of SEC and reconstitution time show statistically significant responses among the formulations.
  • FIG. 2 shows the comparison of model predictions and experimental observation for the test samples.
  • FIG. 3 shows the comparison of model predictions and experimental observation for the controls.
  • FIG. 4 shows the model coefficients of main effect and interaction effect.
  • sucrose and mannitol stabilize the protein against aggregation (sucrose>mannitol).
  • Sucrose has a favorable effect in reducing the reconstitution time. Using high concentrations of sucrose and mannitol, formulation stability is enhanced and cakes with short reconstitution time are obtained.
  • the results indicate that serine and mannitol stabilize the protein against aggregation (mannitol>serine).
  • serine increases the reconstitution time.
  • Formulation stability is enhanced using high concentrations of serine and mannitol, and their combination significantly reduces the reconstitution time.
  • Model simulations allow selection of conditions that provide isotonic formulations. Data supports maximizing the sucrose concentration. At 100 mM sucrose, the model provides conditions for optimizing serine and/or mannitol.
  • Sucrose had the strongest stabilizing effect on the lyophile stability, it also provides a cake with a short reconstitution time.
  • Formulations 1 and 2 were prepared and lyophilized according to procedures similar to those described in Example 1. The lyophilized formulation was incubated at 37° C. for 2.5 months. The lyophilized formulation at different time point was reconstituted with 1 mL water and tested by analytical methods.
  • T0 The formulation has been lyophilized and immediately after this reconstituted with 1 mL water for injection
  • T 2.5 months: The formulation was lyophilized; the cake was incubated at 37° C. for two and half months, then reconstituted with 1 mL water for injection (WFI).
  • Formulation I (FORM-I): 50 mg/mL anti-IL2 receptor antibody, 20 mM Histidine, 4% (117 mM) sucrose, 0.015% Tween® 80, pH 6.0.
  • Formulation II 80 mg/mL protein, 20 mM Histidine, 6.5% (190 mM) sucrose, 0.025% Tween 80, pH 6.0.
  • Formulation III 80 mg/mL protein, 20 mM Histidine, 4% sucrose, 0.015% Tween 80, pH 6.0.
  • FIG. 9 shows the % monomer measured by size exclusion chromatography for the three formulations as a function of time and temperature. At 5° C., over the 3 month duration, no significant change is observed in the monomer content of the three formulations. At 25 and 40° C., over the 3 month duration, less than 3% drop in the monomer content is observed for all three formulations compared with To.
  • FIG. 10 shows the % aggregates measured by size exclusion chromatography for the three formulations as a function of time and temperature. No significant increase in aggregation is observed at 5° C. At 25° C. for 3 months, the increase in aggregation for FORM-I and FORM-II is ⁇ 1% and ⁇ 2% for FORM-III. At 40° C. for 3 months, the increase in aggregation for FORM-I and FORM-II is about 2.5% and ⁇ 4% for FORM-III.
  • FIG. 11 shows the % clips measured by size exclusion chromatography for the three formulations as a function of time and temperature. Minimal changes in the % clips are observed for all three formulations over the three month duration at all temperatures. Thus, hydrolysis, which was a significant stability concern in the aqueous state, has been successfully curtailed in the lyophilized formulation.
  • FTIR Fourier Transform Infrared Spectroscopy
US10/206,469 2001-07-25 2002-07-25 Stable lyophilized pharmaceutical formulation of IgG antibodies Abandoned US20030113316A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/206,469 US20030113316A1 (en) 2001-07-25 2002-07-25 Stable lyophilized pharmaceutical formulation of IgG antibodies
US11/250,835 US7592004B2 (en) 2001-07-25 2005-10-14 Stable lyophilized pharmaceutical formulation of IgG antibodies
US12/540,320 US8298530B2 (en) 2001-07-25 2009-08-12 Stable lyophilized pharmaceutical formulation of IgG antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30787801P 2001-07-25 2001-07-25
US10/206,469 US20030113316A1 (en) 2001-07-25 2002-07-25 Stable lyophilized pharmaceutical formulation of IgG antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/250,835 Continuation US7592004B2 (en) 2001-07-25 2005-10-14 Stable lyophilized pharmaceutical formulation of IgG antibodies

Publications (1)

Publication Number Publication Date
US20030113316A1 true US20030113316A1 (en) 2003-06-19

Family

ID=23191544

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/206,469 Abandoned US20030113316A1 (en) 2001-07-25 2002-07-25 Stable lyophilized pharmaceutical formulation of IgG antibodies
US11/250,835 Expired - Lifetime US7592004B2 (en) 2001-07-25 2005-10-14 Stable lyophilized pharmaceutical formulation of IgG antibodies
US12/540,320 Expired - Lifetime US8298530B2 (en) 2001-07-25 2009-08-12 Stable lyophilized pharmaceutical formulation of IgG antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/250,835 Expired - Lifetime US7592004B2 (en) 2001-07-25 2005-10-14 Stable lyophilized pharmaceutical formulation of IgG antibodies
US12/540,320 Expired - Lifetime US8298530B2 (en) 2001-07-25 2009-08-12 Stable lyophilized pharmaceutical formulation of IgG antibodies

Country Status (10)

Country Link
US (3) US20030113316A1 (ja)
EP (1) EP1409018B1 (ja)
JP (1) JP4317010B2 (ja)
AT (1) ATE454137T1 (ja)
AU (1) AU2002324556A1 (ja)
CA (1) CA2454587C (ja)
DE (1) DE60235013D1 (ja)
ES (1) ES2338218T3 (ja)
MX (1) MXPA04000747A (ja)
WO (1) WO2003009817A2 (ja)

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236196A1 (en) * 2002-06-20 2003-12-25 Amgen Inc. Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US20050175603A1 (en) * 2000-10-12 2005-08-11 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20060217311A1 (en) * 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
US20060269543A1 (en) * 2005-05-19 2006-11-30 Amgen Inc. Compositions and methods for increasing the stability of antibodies
US20070116729A1 (en) * 2005-11-18 2007-05-24 Palepu Nageswara R Lyophilization process and products obtained thereby
US20070172479A1 (en) * 2005-12-21 2007-07-26 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
US20080015148A1 (en) * 2004-08-17 2008-01-17 Daniel Dix IL-1 Antagonist Formulations
US20080038258A1 (en) * 2006-07-21 2008-02-14 Amgen Inc. Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
US20080124326A1 (en) * 2006-10-20 2008-05-29 Amgen Inc. Stable polypeptide formulations
US20080139792A1 (en) * 2006-12-06 2008-06-12 Wyeth High Protein Concentration Formulations Containing Mannitol
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
WO2008101179A2 (en) * 2007-02-16 2008-08-21 Wyeth Use of sucrose to suppress mannitol-induced protein aggregation
US20080200655A1 (en) * 2007-02-16 2008-08-21 Wyeth Protein Formulations Containing Sorbitol
US20080213277A1 (en) * 2007-02-02 2008-09-04 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US20080249017A1 (en) * 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
US20080292639A1 (en) * 2005-01-24 2008-11-27 Amgen Inc. Humanized Anti-Amyloid Antibody
US20090060906A1 (en) * 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20090306348A1 (en) * 2006-02-15 2009-12-10 Imclone Systems Incorporated Antibody Formulation
US20100015157A1 (en) * 2004-10-20 2010-01-21 Genentech, Inc. Antibody formulations
US20100021461A1 (en) * 2003-02-10 2010-01-28 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
JP2010530003A (ja) * 2007-06-14 2010-09-02 エラン ファーマシューティカルズ，インコーポレイテッド 凍結乾燥免疫グロブリン製剤および調製方法
US20100239567A1 (en) * 2009-03-06 2010-09-23 Genentech, Inc. Antibody Formulation
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011063277A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
WO2011061712A1 (en) * 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
US20110171241A1 (en) * 2010-01-08 2011-07-14 Regeneron Pharmaceuticals, Inc. Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies
WO2012009254A1 (en) * 2010-07-14 2012-01-19 Regeneron Pharmaceuticals, Inc Stabilized formulations containing anti-ngf antibodies
WO2012003470A3 (en) * 2010-07-02 2012-02-23 Medimmune, Llc Antibody formulations
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
US20120093839A1 (en) * 2009-03-05 2012-04-19 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
WO2012172072A1 (en) * 2011-06-17 2012-12-20 Ares Trading S.A. Freeze-dried formulations of fgf-18
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8795669B2 (en) 2011-07-28 2014-08-05 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9402898B2 (en) 2012-01-23 2016-08-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US9550837B2 (en) 2008-12-15 2017-01-24 Regeneron Pharmaceuticals, Inc. Therapeutic uses of anti-PCSK9 antibodies
US9561155B2 (en) 2011-01-28 2017-02-07 Sanofi Biotechnology Method of reducing cholesterol levels using a human anti-PCSK9 antibody
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
US9605051B2 (en) 2014-06-20 2017-03-28 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US9675692B2 (en) 2012-05-31 2017-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-DLL4 antibodies
US9724411B2 (en) 2008-12-15 2017-08-08 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
US9833513B2 (en) 2013-09-11 2017-12-05 Eagle Biologics, Inc. Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
US9884117B2 (en) 2009-09-03 2018-02-06 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
US10000573B2 (en) 2008-03-14 2018-06-19 Centro De Immunologia Molecular Monoclonal antibody and a method thereof
US10076571B2 (en) 2011-09-16 2018-09-18 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP3385279A1 (en) 2009-03-20 2018-10-10 Amgen Inc. Carrier immunoglobulins and uses thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
WO2018222991A2 (en) 2017-06-02 2018-12-06 Amgen Inc. Peptide pac1 antagonists
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
EP3453724A1 (en) 2006-04-24 2019-03-13 Amgen Inc. Humanized c-kit antibody
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US10517830B2 (en) * 2011-10-25 2019-12-31 Prothena Biosciences Limited Antibody formulations and methods
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
CN111110638A (zh) * 2020-01-10 2020-05-08 广州市丹蓝生物科技有限公司 一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
US10927435B2 (en) 2011-10-11 2021-02-23 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US11066458B2 (en) 2006-06-16 2021-07-20 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
WO2021183423A1 (en) * 2020-03-09 2021-09-16 Idexx Laboratories, Inc. Method for removing interfering components of a liquid sample prior to dispensing same on a chemical reagent test slide
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
US11253572B2 (en) 2011-01-13 2022-02-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
US11769597B2 (en) 2015-12-03 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11981743B2 (en) 2008-03-14 2024-05-14 Biocon Limited Monoclonal antibody and a method thereof

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
PT1778723E (pt) * 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2006096490A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2615122A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
WO2007112047A2 (en) * 2006-03-24 2007-10-04 Enzon Pharmaceuticals, Inc. Formulations containing immunotoxins targeted to the mesothelin tumor cell antigen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2052723A4 (en) * 2006-08-14 2010-07-28 Eisai R&D Man Co Ltd STABLE LYOPHILIZED PREPARATION
CA2671968A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
US20100260766A1 (en) * 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN107184976A (zh) * 2008-11-20 2017-09-22 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
PT2448970E (pt) * 2009-05-04 2014-10-20 Abbvie Res B V Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada
WO2010148321A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Slow dissolution method for reconstitution of lyophilized material
EP2473851A1 (en) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
CA2774286A1 (en) 2009-10-30 2011-05-05 Abbott Biotherapeutics Corp. Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
CN108785654A (zh) 2009-11-23 2018-11-13 丘比斯特制药有限责任公司 脂肽组合物和相关方法
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
AU2011227335B2 (en) * 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
US20130136733A1 (en) * 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
MX344727B (es) * 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
CA2829629A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
TR201810298T4 (tr) 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SG11201405475UA (en) * 2012-03-07 2014-10-30 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US9441051B2 (en) * 2012-11-26 2016-09-13 Albert Ludwigs Universitäfreiburg Matrices comprising modified polysaccharides and modified polysaccharides
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
TW201605468A (zh) * 2013-09-27 2016-02-16 韓美藥品股份有限公司 長效人類生長激素接合物之製劑
WO2015058173A1 (en) * 2013-10-18 2015-04-23 Abbvie Inc. Stable solid units and methods of making the same
KR102372245B1 (ko) 2013-11-21 2022-03-08 젠맵 에이/에스 항체-약물 접합체 동결건조 제제
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR20230033737A (ko) 2014-05-27 2023-03-08 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
KR20220151036A (ko) * 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
JP6634394B2 (ja) * 2014-06-26 2020-01-22 アムジェン インコーポレイテッド タンパク質製剤
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
BR112017003419A2 (pt) * 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
DK3287139T3 (da) 2015-04-21 2021-09-13 Beijing Staidson Medical Tech Co Ltd Nervevækstfaktorsammensætning og injektionspulver
EP3287140B1 (en) 2015-04-21 2021-06-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
HRP20220304T1 (hr) 2015-06-24 2022-05-13 F. Hoffmann - La Roche Ag Anti-transferinska receptorska protutijela s prilagođenim afinitetom
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN108602827B (zh) 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
WO2017112621A1 (en) * 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
SG11201805534TA (en) 2016-01-13 2018-07-30 Genmab As Formulation for antibody and drug conjugate thereof
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2017212494A1 (en) 2016-06-09 2017-12-14 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
TW202308683A (zh) * 2016-11-02 2023-03-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
CN110856446A (zh) * 2017-04-18 2020-02-28 阿法姆海外股份有限公司 抗pd-l1抗体及其用途
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
EP4333878A1 (en) * 2021-05-07 2024-03-13 Dr. Reddy's Laboratories Limited A method of improving stability of an antibody formulation
CN117500834A (zh) * 2021-06-21 2024-02-02 百时美施贵宝公司 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618486A (en) * 1983-01-21 1986-10-21 Monocarb Ab Monoclonal antibody formulation for diagnostic use
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5677171A (en) * 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5714477A (en) * 1993-06-18 1998-02-03 Pharmacia & Upjohn Aktiebolag Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US5783592A (en) * 1994-01-07 1998-07-21 Baylor College Of Medicine Formulations for lipophilic compounds
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5827818A (en) * 1995-03-21 1998-10-27 Immuno Aktiengesellschaft Agent for subcutaneous administration of protein C
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010014326A1 (en) * 1995-07-27 2001-08-16 Genentech, Inc. Protein formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
EP0417193B1 (en) * 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
DE69810481T2 (de) * 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618486A (en) * 1983-01-21 1986-10-21 Monocarb Ab Monoclonal antibody formulation for diagnostic use
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5677171A (en) * 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5714477A (en) * 1993-06-18 1998-02-03 Pharmacia & Upjohn Aktiebolag Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
US5783592A (en) * 1994-01-07 1998-07-21 Baylor College Of Medicine Formulations for lipophilic compounds
US5827818A (en) * 1995-03-21 1998-10-27 Immuno Aktiengesellschaft Agent for subcutaneous administration of protein C
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010014326A1 (en) * 1995-07-27 2001-08-16 Genentech, Inc. Protein formulation
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation

Cited By (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166293B2 (en) 2000-10-12 2019-01-01 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20070116700A1 (en) * 2000-10-12 2007-05-24 Genentech, Inc. Reduced-Viscosity Concentrated Protein Formulations
US7666413B2 (en) 2000-10-12 2010-02-23 Genetech, Inc. Method of reducing viscosity of high concentration protein formulations
US20050175603A1 (en) * 2000-10-12 2005-08-11 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8142776B2 (en) 2000-10-12 2012-03-27 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030236196A1 (en) * 2002-06-20 2003-12-25 Amgen Inc. Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7700722B2 (en) 2002-06-20 2010-04-20 Amgen Inc. Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US10954303B2 (en) 2003-02-10 2021-03-23 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
US8815236B2 (en) 2003-02-10 2014-08-26 Biogen Idec Ma Inc. Method for treating multiple sclerosis and crohn's disease
US8349321B2 (en) 2003-02-10 2013-01-08 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US20100021461A1 (en) * 2003-02-10 2010-01-28 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US8900577B2 (en) 2003-02-10 2014-12-02 Biogen Idec Ma Inc. Immunoglobulin formulation and method of preparation thereof
US10034940B2 (en) 2003-04-04 2018-07-31 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8961964B2 (en) 2003-04-04 2015-02-24 Genentech, Inc. High concentration antibody and protein formulations
US20090280129A1 (en) * 2003-04-04 2009-11-12 Genentech, Inc. High concentration antibody and protein formulations
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
US20070086995A1 (en) * 2003-04-04 2007-04-19 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
US20070053900A1 (en) * 2003-04-04 2007-03-08 Genentech, Inc. High concentration antibody and protein formulations
WO2006014965A3 (en) * 2004-07-27 2007-03-29 Human Genome Sciences Inc Pharmaceutical formulation and process
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20080015148A1 (en) * 2004-08-17 2008-01-17 Daniel Dix IL-1 Antagonist Formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7572893B2 (en) 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP2371388A2 (en) 2004-10-20 2011-10-05 Genentech, Inc. Antibody formulations
EP3498294A1 (en) 2004-10-20 2019-06-19 Genentech, Inc. Antibody formulations
US8372396B2 (en) 2004-10-20 2013-02-12 Genetech, Inc. Antibody formulations
US20100015157A1 (en) * 2004-10-20 2010-01-21 Genentech, Inc. Antibody formulations
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US20080292639A1 (en) * 2005-01-24 2008-11-27 Amgen Inc. Humanized Anti-Amyloid Antibody
US9511140B2 (en) 2005-03-25 2016-12-06 Regeneron Pharmaceuticals, Inc. Stable VEGF antagonist formulations
US10857231B2 (en) 2005-03-25 2020-12-08 Regeneron Pharmaceuticals, Inc. Formulations of VEG antagonist fusion proteins and method of manufacturing them
US8710004B2 (en) 2005-03-25 2014-04-29 Regeneron Pharmaceuticals, Inc. Stable liquid VEGF antagonist formulations
US20060217311A1 (en) * 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
US10406226B2 (en) 2005-03-25 2019-09-10 Regeneron Pharmaceuticals, Inc. Method of manufacturing VEGF antagonist fusion proteins
US9636400B2 (en) 2005-03-25 2017-05-02 Regeneron Pharmaceuticals, Inc. VEGF specific fusion protein antagonist formulations
US9416167B2 (en) 2005-03-25 2016-08-16 Regeneron Pharmaceuticals, Inc. Stable liquid formulations of dimer VEGF antagonists
US8921316B2 (en) 2005-03-25 2014-12-30 Regeneron Pharmaceuticals, Inc. Stable liquid VEGF antagonist formulations
US11806398B2 (en) 2005-03-25 2023-11-07 Regeneron Pharmaceuticals, Inc. Citrate buffered VEGF antagonist formulations
US8404638B2 (en) 2005-03-25 2013-03-26 Regeneron Pharmaceuticals, Inc. Dimer VEGF antagonist formulations
US20060269543A1 (en) * 2005-05-19 2006-11-30 Amgen Inc. Compositions and methods for increasing the stability of antibodies
US8858935B2 (en) 2005-05-19 2014-10-14 Amgen Inc. Compositions and methods for increasing the stability of antibodies
US20070116729A1 (en) * 2005-11-18 2007-05-24 Palepu Nageswara R Lyophilization process and products obtained thereby
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7758860B2 (en) 2005-12-21 2010-07-20 Wyeth Llc Protein formulations with reduced viscosity and uses thereof
US20110027292A1 (en) * 2005-12-21 2011-02-03 Wyeth Llc Protein Formulations with Reduced Viscosity and Uses Thereof
US20070172479A1 (en) * 2005-12-21 2007-07-26 Wyeth Protein formulations with reduced viscosity and uses thereof
US7390786B2 (en) 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
US20090306348A1 (en) * 2006-02-15 2009-12-10 Imclone Systems Incorporated Antibody Formulation
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
EP3453724A1 (en) 2006-04-24 2019-03-13 Amgen Inc. Humanized c-kit antibody
US11084865B2 (en) 2006-06-16 2021-08-10 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US11732024B2 (en) 2006-06-16 2023-08-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US11066458B2 (en) 2006-06-16 2021-07-20 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US20080038258A1 (en) * 2006-07-21 2008-02-14 Amgen Inc. Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US20100158908A1 (en) * 2006-10-20 2010-06-24 Amgen Inc. Stable Polypeptide Formulations
US20080124326A1 (en) * 2006-10-20 2008-05-29 Amgen Inc. Stable polypeptide formulations
US8241632B2 (en) 2006-10-20 2012-08-14 Amgen Inc. Stable polypeptide formulations
WO2008070721A2 (en) * 2006-12-06 2008-06-12 Wyeth High protein concentration formulations containing mannitol
US20080139792A1 (en) * 2006-12-06 2008-06-12 Wyeth High Protein Concentration Formulations Containing Mannitol
WO2008070721A3 (en) * 2006-12-06 2008-09-18 Wyeth Corp High protein concentration formulations containing mannitol
US20090060906A1 (en) * 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20080213277A1 (en) * 2007-02-02 2008-09-04 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US8629250B2 (en) 2007-02-02 2014-01-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
WO2008101179A3 (en) * 2007-02-16 2008-12-24 Wyeth Corp Use of sucrose to suppress mannitol-induced protein aggregation
US20080200655A1 (en) * 2007-02-16 2008-08-21 Wyeth Protein Formulations Containing Sorbitol
WO2008101179A2 (en) * 2007-02-16 2008-08-21 Wyeth Use of sucrose to suppress mannitol-induced protein aggregation
US20080249017A1 (en) * 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
JP2010530003A (ja) * 2007-06-14 2010-09-02 エラン ファーマシューティカルズ，インコーポレイテッド 凍結乾燥免疫グロブリン製剤および調製方法
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
WO2009037190A3 (en) * 2007-09-21 2009-05-14 Hoffmann La Roche Pharmaceutical formulation for il-ir antibody
US20090208509A1 (en) * 2007-09-21 2009-08-20 Roche Palo Alto Llc Pharmaceutical formulation of an antibody against IL-1R
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2261254A2 (en) 2007-12-21 2010-12-15 Amgen, Inc Anti-amyloid antibodies and uses thereof
EP2574628A1 (en) 2008-01-25 2013-04-03 Amgen Inc. Ferroportin antibodies and methods of use
US9688759B2 (en) 2008-01-25 2017-06-27 Amgen, Inc. Ferroportin antibodies and methods of use
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2803675A2 (en) 2008-01-25 2014-11-19 Amgen, Inc Ferroportin antibodies and methods of use
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US10669346B2 (en) 2008-03-14 2020-06-02 Biocon Limited Monoclonal antibody and a method thereof
US11981743B2 (en) 2008-03-14 2024-05-14 Biocon Limited Monoclonal antibody and a method thereof
US10000573B2 (en) 2008-03-14 2018-06-19 Centro De Immunologia Molecular Monoclonal antibody and a method thereof
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2816059A1 (en) 2008-05-01 2014-12-24 Amgen, Inc Anti-hepcidin antibodies and methods of use
US10023654B2 (en) 2008-12-15 2018-07-17 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US9724411B2 (en) 2008-12-15 2017-08-08 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
US10941210B2 (en) 2008-12-15 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US9550837B2 (en) 2008-12-15 2017-01-24 Regeneron Pharmaceuticals, Inc. Therapeutic uses of anti-PCSK9 antibodies
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20120093839A1 (en) * 2009-03-05 2012-04-19 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US10919954B2 (en) 2009-03-05 2021-02-16 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US10005830B2 (en) * 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US8318161B2 (en) 2009-03-06 2012-11-27 Genentech, Inc. Anti-oxidized LDL antibody formulation
US20100239567A1 (en) * 2009-03-06 2010-09-23 Genentech, Inc. Antibody Formulation
EP3385279A1 (en) 2009-03-20 2018-10-10 Amgen Inc. Carrier immunoglobulins and uses thereof
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US20140141008A1 (en) * 2009-05-04 2014-05-22 Abbvie Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US20140141007A1 (en) * 2009-05-04 2014-05-22 Abbvie Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9884117B2 (en) 2009-09-03 2018-02-06 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AU2010320515B2 (en) * 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
WO2011063277A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
WO2011061712A1 (en) * 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
CN102770157A (zh) * 2009-11-20 2012-11-07 拜康有限公司 抗体的配制品
JP2013511510A (ja) * 2009-11-20 2013-04-04 バイオコン リミテッド 抗体製剤
KR101333276B1 (ko) 2009-11-20 2013-11-27 센트로 데 인무노로지아 몰레큘라 항체의 제제
US9173880B2 (en) 2010-01-08 2015-11-03 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
US20110171241A1 (en) * 2010-01-08 2011-07-14 Regeneron Pharmaceuticals, Inc. Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies
EP4098247A1 (en) * 2010-01-08 2022-12-07 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
US11098127B2 (en) 2010-01-08 2021-08-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
EP3409269A1 (en) * 2010-01-08 2018-12-05 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
WO2011085158A3 (en) * 2010-01-08 2012-03-22 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
EP3756652A1 (en) * 2010-01-08 2020-12-30 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
KR101787351B1 (ko) * 2010-01-08 2017-10-19 리제너론 파아마슈티컬스, 인크. 항―인터류킨―６ 수용체（ｉｌ―６ｒ） 항체를 함유하는 안정화된 제형
US10072086B2 (en) 2010-01-08 2018-09-11 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US8754195B2 (en) 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
WO2012003470A3 (en) * 2010-07-02 2012-02-23 Medimmune, Llc Antibody formulations
CN103108658A (zh) * 2010-07-02 2013-05-15 米迪缪尼有限公司 抗体制剂
TWI481414B (zh) * 2010-07-14 2015-04-21 Regeneron Pharma 含抗－ｎｇｆ抗體之穩定化調配物
AU2015202886B2 (en) * 2010-07-14 2016-04-21 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ngf antibodies
AU2011279450B2 (en) * 2010-07-14 2015-03-19 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-NGF antibodies
AU2016204515B2 (en) * 2010-07-14 2017-10-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ngf antibodies
WO2012009254A1 (en) * 2010-07-14 2012-01-19 Regeneron Pharmaceuticals, Inc Stabilized formulations containing anti-ngf antibodies
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
US11559564B2 (en) 2011-01-13 2023-01-24 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11707506B2 (en) 2011-01-13 2023-07-25 Regeneren Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11253572B2 (en) 2011-01-13 2022-02-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11730794B2 (en) 2011-01-13 2023-08-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11975045B2 (en) 2011-01-13 2024-05-07 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US9561155B2 (en) 2011-01-28 2017-02-07 Sanofi Biotechnology Method of reducing cholesterol levels using a human anti-PCSK9 antibody
US9682013B2 (en) 2011-01-28 2017-06-20 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to PCSK9
US11246925B2 (en) 2011-01-28 2022-02-15 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US9326944B2 (en) 2011-06-17 2016-05-03 Ares Trading S.A. Freeze-dried formulations of FGF-18
AU2012268987B2 (en) * 2011-06-17 2016-09-08 Ares Trading S.A. Freeze-dried formulations of FGF-18
WO2012172072A1 (en) * 2011-06-17 2012-12-20 Ares Trading S.A. Freeze-dried formulations of fgf-18
EA024937B1 (ru) * 2011-06-17 2016-11-30 Арес Трейдинг С.А. Лиофилизированные препараты fgf-18
EP3056211A1 (en) * 2011-06-17 2016-08-17 Ares Trading S.A. Freeze-dried formulations of fgf-18
US9193801B2 (en) 2011-07-28 2015-11-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US8795669B2 (en) 2011-07-28 2014-08-05 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10752701B2 (en) 2011-07-28 2020-08-25 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10472425B2 (en) 2011-07-28 2019-11-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US11116839B2 (en) 2011-09-16 2021-09-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10076571B2 (en) 2011-09-16 2018-09-18 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10927435B2 (en) 2011-10-11 2021-02-23 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
US10517830B2 (en) * 2011-10-25 2019-12-31 Prothena Biosciences Limited Antibody formulations and methods
US9402898B2 (en) 2012-01-23 2016-08-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US9675692B2 (en) 2012-05-31 2017-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-DLL4 antibodies
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US9803011B2 (en) 2013-03-15 2017-10-31 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10239941B2 (en) 2013-03-15 2019-03-26 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
US11028168B2 (en) 2013-07-23 2021-06-08 Biocon Limited Use of a CD6 binding partner and method based thereon
US10821183B2 (en) 2013-09-11 2020-11-03 Eagle Biologics, Inc. Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)
US10646571B2 (en) 2013-09-11 2020-05-12 Eagle Biologics, Inc. Liquid protein formulations containing cimetidine
US11819550B2 (en) 2013-09-11 2023-11-21 Eagle Biologics, Inc. Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)
US10849977B2 (en) 2013-09-11 2020-12-01 Eagle Biologics, Inc. Liquid Protein Formulations Containing Thiamine
US9925263B2 (en) 2013-09-11 2018-03-27 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising procaine and uses thereof
US9913905B2 (en) 2013-09-11 2018-03-13 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof
US10821184B2 (en) 2013-09-11 2020-11-03 Eagle Biologics, Inc. Liquid protein formulations containing thiamine pyrophosphate (TPP)
US10179172B2 (en) 2013-09-11 2019-01-15 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof
US9833513B2 (en) 2013-09-11 2017-12-05 Eagle Biologics, Inc. Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US11806399B2 (en) 2014-06-20 2023-11-07 Comera Life Sciences, Inc. Excipient compounds for biopolymer formulations
US11696951B2 (en) 2014-06-20 2023-07-11 Comera Life Sciences, Inc. Viscosity-reducing compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US9605051B2 (en) 2014-06-20 2017-03-28 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11672865B2 (en) 2014-06-20 2023-06-13 Comera Life Sciences, Inc. Viscosity-reducing excipient compounds for protein formulations
US11660343B2 (en) 2014-06-20 2023-05-30 Comera Life Sciences, Inc. Viscosity-reducing excipient compounds for protein formulations
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
US11769597B2 (en) 2015-12-03 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
WO2018222991A2 (en) 2017-06-02 2018-12-06 Amgen Inc. Peptide pac1 antagonists
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
CN111110638A (zh) * 2020-01-10 2020-05-08 广州市丹蓝生物科技有限公司 一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式
WO2021183423A1 (en) * 2020-03-09 2021-09-16 Idexx Laboratories, Inc. Method for removing interfering components of a liquid sample prior to dispensing same on a chemical reagent test slide

Also Published As

Publication number Publication date
WO2003009817A3 (en) 2003-11-27
WO2003009817B1 (en) 2003-12-18
EP1409018A4 (en) 2007-03-28
EP1409018A2 (en) 2004-04-21
WO2003009817A2 (en) 2003-02-06
EP1409018B1 (en) 2010-01-06
JP4317010B2 (ja) 2009-08-19
CA2454587C (en) 2012-11-13
ES2338218T3 (es) 2010-05-05
AU2002324556A1 (en) 2003-02-17
US20060029599A1 (en) 2006-02-09
US8298530B2 (en) 2012-10-30
JP2004538287A (ja) 2004-12-24
WO2003009817A9 (en) 2004-05-06
US20100055097A1 (en) 2010-03-04
DE60235013D1 (de) 2010-02-25
ATE454137T1 (de) 2010-01-15
US7592004B2 (en) 2009-09-22
CA2454587A1 (en) 2003-02-06
MXPA04000747A (es) 2004-07-08

Similar Documents

Publication Publication Date Title
US7592004B2 (en) Stable lyophilized pharmaceutical formulation of IgG antibodies
US8465739B2 (en) Stable aqueous pharmaceutical formulations of daclizumab antibodies
US7390786B2 (en) Protein formulations with reduced viscosity and uses thereof
RU2497500C2 (ru) Стабильная изотоническая лиофилизированная протеиновая композиция
AU2002363339A1 (en) Stable liquid pharmaceutical formulation of IGG antibodies
MXPA98000684A (en) Formulation of isotonic protocols isotonic s
WO2004039337A2 (en) Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20090068196A1 (en) Pharmaceutical formulation of an antibody against IL13Ralpha1
MX2008008021A (es) Formulaciones de proteina con viscosidad reductiva y sus usos

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROTEIN DESIGN LABS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAISHEVA, ELIZABET A.;FLORES-NATE, ALENI;GUPTA, SUPRIYA;REEL/FRAME:013400/0018;SIGNING DATES FROM 20020909 TO 20020910

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION